Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals in the countries. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland. Under this procurement group, the pharmaceuticals are tendered under each procurement no. for the purpose of supplying the Contracting Authorities as 2 markets (Norway as 1 market and Denmark and Iceland as 1 market) see section II.2.4 and the tender specification.
The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.
Deadline
Fristen for modtagelse af bud var på 2021-08-31.
Indkøbet blev offentliggjort på 2021-06-09.
Leverandører
Følgende leverandører er nævnt i tildelingsbeslutninger eller andre indkøbsdokumenter:
Ordregivende myndighed
E-mail: legemidler@sykehusinnkjop.no📧
Region: Norge 🏙️
URL: http://www.sykehusinnkjop.no🌏 Oplysninger om fælles indkøb
Kontrakten omfatter fælles indkøb
I tilfælde af fælles indkøb, der involverer forskellige lande, angives den gældende nationale udbudslovgivning: Danish law
Kommunikation
URL til dokumenter: www.amgros.dk🌏
Objekt Omfanget af udbuddet
Titel: Joint Nordic Procurement of Pharmaceuticals — 2022 — NF2.603.a
Produkter/tjenester: Lægemidler📦
Kort beskrivelse:
“Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award...”
Kort beskrivelse
Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals in the countries. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland. Under this procurement group, the pharmaceuticals are tendered under each procurement no. for the purpose of supplying the Contracting Authorities as 2 markets (Norway as 1 market and Denmark and Iceland as 1 market) see section II.2.4 and the tender specification.
The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.
Vis mere
Anslået værdi uden moms: EUR 8 000 000 💰
Oplysninger om partier
Der kan afgives bud for alle partier
1️⃣ Omfanget af udbuddet
Titel: 1
Titel
Partiets identifikationsnummer: 1
Beskrivelse
Yderligere produkter/tjenester: Lægemidler📦
Sted for udførelsen: Danmark🏙️
Sted for udførelsen: Ísland 🏙️
Sted for udførelsen: Norge 🏙️
Beskrivelse af udbuddet:
“ATC Code: A04AA01
Generic Name: Ondansetrone
Pharmaceutical form: Injection Fluid
Strenght: 2 mg/ml
Package: 2 ml
Unit: 16 mg
Volume in units: (Denmark...”
Beskrivelse af udbuddet
ATC Code: A04AA01
Generic Name: Ondansetrone
Pharmaceutical form: Injection Fluid
Strenght: 2 mg/ml
Package: 2 ml
Unit: 16 mg
Volume in units: (Denmark 186.598) (Iceland 10)
ATC Code: A04AA01
Generic Name: Ondansetrone
Pharmaceutical form: Injection Fluid
Strenght: 2 mg/ml
Package: 4 ml
Unit: 16 mg
Volume in units: (Denmark 17.010) (Iceland 6.493)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. However, the aim is to conclude framework agreements with different suppliers for the procurement numbers 1 and 2, which are linked procurement numbers.
If there is only one compliant tender for either procurement numbers 1 or 2, the framework agreement for the procurement number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two procurement numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ra-tio”.
If there are several compliant tenders for both procurement numbers 1 and 2, the award under pro-curement number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both procurement numbers 1 and 2, and there are several com-pliant tenders for both procurement numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for procurement number 1, since the framework agreement for procurement number 2 is awarded to the supplier with the “second best price-quality ratio” under the procurement number concerned.
If there is only one compliant tender for both procurement numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both procurement numbers 1 and 2.
For every single pharmaceutical, a maximum price has been determined (price per unit ex. VAT) stated in Appendix A. Tenders with prices that exceed the set maximum price will be considered non-compliant and will not be able to form a basis for conclusion of framework agreement, see the tender specifications section 10.3
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”), the Norwegian "Farmalogg" and the Icelandic “Lyfjaverðskrá” not later than 21 February 2022 in order to ensure supply from the beginning of the Purchase Period.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
Vis mere Kriterier for tildeling
Prisen er ikke det eneste tildelingskriterium, og alle kriterier er kun anført i udbudsdokumenterne
Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 790 400 💰
Varighed
Startdato: 2022-04-01 📅
Slutdato: 2024-03-31 📅
Kontraktens, rammeaftalens eller det dynamiske indkøbssystems varighed
Denne kontrakt kan forlænges ✅ Beskrivelse
Beskrivelse af fornyelser:
“The contracting authorities shall be entitled to extend the framework agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by...”
Beskrivelse af fornyelser
The contracting authorities shall be entitled to extend the framework agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by up to 12 months.
Vis mere Oplysninger om valgmuligheder
Indstillinger ✅
Beskrivelse af mulighederne:
“Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option...”
Beskrivelse af mulighederne
Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement.
2️⃣ Omfanget af udbuddet
Titel: 2
Titel
Partiets identifikationsnummer: 2
Beskrivelse
Beskrivelse af udbuddet:
“ATC Code: A04AA01
Generic Name: Ondansetrone
Pharmaceutical form: Injection Fluid
Strenght: 2 mg/ml
Package: 2 ml
Unit: 16 mg
Volume in units: Norway...”
Beskrivelse af udbuddet
ATC Code: A04AA01
Generic Name: Ondansetrone
Pharmaceutical form: Injection Fluid
Strenght: 2 mg/ml
Package: 2 ml
Unit: 16 mg
Volume in units: Norway 110.000
ATC Code: A04AA01
Generic Name: Ondansetrone
Pharmaceutical form: Injection Fluid
Strenght: 2 mg/ml
Package: 4 ml
Unit: 16 mg
Volume in units: Norway 13.000
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. However, the aim is to conclude framework agreements with different suppliers for the procurement numbers 1 and 2, which are linked procurement numbers.
If there is only one compliant tender for either procurement numbers 1 or 2, the framework agreement for the procurement number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two procurement numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ra-tio”.
If there are several compliant tenders for both procurement numbers 1 and 2, the award under pro-curement number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both procurement numbers 1 and 2, and there are several com-pliant tenders for both procurement numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for procurement number 1, since the framework agreement for procurement number 2 is awarded to the supplier with the “second best price-quality ratio” under the procurement number concerned.
If there is only one compliant tender for both procurement numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both procurement numbers 1 and 2.
For every single pharmaceutical, a maximum price has been determined (price per unit ex. VAT) stated in Appendix A. Tenders with prices that exceed the set maximum price will be considered non-compliant and will not be able to form a basis for conclusion of framework agreement, see the tender specifications section 10.3
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”), the Norwegian "Farmalogg" and the Icelandic “Lyfjaverðskrá” not later than 21 February 2022 in order to ensure supply from the beginning of the Purchase Period.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 949 000 💰
Beskrivelse
Beskrivelse af fornyelser:
“The Contracting Authorities shall be entitled to extend the framework agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by...”
Beskrivelse af fornyelser
The Contracting Authorities shall be entitled to extend the framework agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by up to 12 months.
3️⃣ Omfanget af udbuddet
Titel: 3
Titel
Partiets identifikationsnummer: 3
Beskrivelse
Beskrivelse af udbuddet:
“ATC Code: J01DC02
Generic Name: Cefuroxime
Pharmaceutical form: Injection Fluid
Strenght: 250 mg
Package: Vial
Unit: 3 g
Volume in units: Norway 4.722
Each...”
Beskrivelse af udbuddet
ATC Code: J01DC02
Generic Name: Cefuroxime
Pharmaceutical form: Injection Fluid
Strenght: 250 mg
Package: Vial
Unit: 3 g
Volume in units: Norway 4.722
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. However, the aim is to conclude framework agreements with different suppliers for the procurement numbers 1 and 2, which are linked procurement numbers.
If there is only one compliant tender for either procurement numbers 1 or 2, the framework agreement for the procurement number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two procurement numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ra-tio”.
If there are several compliant tenders for both procurement numbers 1 and 2, the award under pro-curement number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both procurement numbers 1 and 2, and there are several com-pliant tenders for both procurement numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for procurement number 1, since the framework agreement for procurement number 2 is awarded to the supplier with the “second best price-quality ratio” under the procurement number concerned.
If there is only one compliant tender for both procurement numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both procurement numbers 1 and 2.
For every single pharmaceutical, a maximum price has been determined (price per unit ex. VAT) stated in Appendix A. Tenders with prices that exceed the set maximum price will be considered non-compliant and will not be able to form a basis for conclusion of framework agreement, see the tender specifications section 10.3
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”), the Norwegian "Farmalogg" and the Icelandic “Lyfjaverðskrá” not later than 21 February 2022 in order to ensure supply from the beginning of the Purchase Period.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 900 💰
4️⃣ Omfanget af udbuddet
Titel: 4
Titel
Partiets identifikationsnummer: 4
Beskrivelse
Beskrivelse af udbuddet:
“ATC Code: J01DC02
Generic Name: Cefuroxime
Pharmaceutical form: Injection Fluid
Strenght: 250 mg
Package: Vial
Unit: 3 g
Volume in units: (Denmark 1.016)...”
Beskrivelse af udbuddet
ATC Code: J01DC02
Generic Name: Cefuroxime
Pharmaceutical form: Injection Fluid
Strenght: 250 mg
Package: Vial
Unit: 3 g
Volume in units: (Denmark 1.016) (Iceland 10)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. However, the aim is to conclude framework agreements with different suppliers for the procurement numbers 1 and 2, which are linked procurement numbers.
If there is only one compliant tender for either procurement numbers 1 or 2, the framework agreement for the procurement number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two procurement numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ra-tio”.
If there are several compliant tenders for both procurement numbers 1 and 2, the award under pro-curement number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both procurement numbers 1 and 2, and there are several com-pliant tenders for both procurement numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for procurement number 1, since the framework agreement for procurement number 2 is awarded to the supplier with the “second best price-quality ratio” under the procurement number concerned.
If there is only one compliant tender for both procurement numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both procurement numbers 1 and 2.
For every single pharmaceutical, a maximum price has been determined (price per unit ex. VAT) stated in Appendix A. Tenders with prices that exceed the set maximum price will be considered non-compliant and will not be able to form a basis for conclusion of framework agreement, see the tender specifications section 10.3
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”), the Norwegian "Farmalogg" and the Icelandic “Lyfjaverðskrá” not later than 21 February 2022 in order to ensure supply from the beginning of the Purchase Period.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
5️⃣ Omfanget af udbuddet
Titel: 5
Titel
Partiets identifikationsnummer: 5
Beskrivelse
Beskrivelse af udbuddet:
“ATC Code: J01DC02
Generic Name: Cefuroxime
Pharmaceutical form: Injection Fluid
Strenght: 750 mg
Package: Vial
Unit: 3 g
Volume in units: (Denmark 48.690)...”
Beskrivelse af udbuddet
ATC Code: J01DC02
Generic Name: Cefuroxime
Pharmaceutical form: Injection Fluid
Strenght: 750 mg
Package: Vial
Unit: 3 g
Volume in units: (Denmark 48.690) (Iceland 520)
ATC Code: J01DC02
Generic Name: Cefuroxime
Pharmaceutical form: Injection Fluid
Strenght: 1500 mg
Package: Vial
Unit: 3 g
Volume in units: (Denmark 349.540) (Iceland 1.550)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. However, the aim is to conclude framework agreements with different suppliers for the procurement numbers 1 and 2, which are linked procurement numbers.
If there is only one compliant tender for either procurement numbers 1 or 2, the framework agreement for the procurement number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two procurement numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ra-tio”.
If there are several compliant tenders for both procurement numbers 1 and 2, the award under pro-curement number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both procurement numbers 1 and 2, and there are several com-pliant tenders for both procurement numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for procurement number 1, since the framework agreement for procurement number 2 is awarded to the supplier with the “second best price-quality ratio” under the procurement number concerned.
If there is only one compliant tender for both procurement numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both procurement numbers 1 and 2.
For every single pharmaceutical, a maximum price has been determined (price per unit ex. VAT) stated in Appendix A. Tenders with prices that exceed the set maximum price will be considered non-compliant and will not be able to form a basis for conclusion of framework agreement, see the tender specifications section 10.3
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”), the Norwegian "Farmalogg" and the Icelandic “Lyfjaverðskrá” not later than 21 February 2022 in order to ensure supply from the beginning of the Purchase Period.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 1 004 000 💰
6️⃣ Omfanget af udbuddet
Titel: 6
Titel
Partiets identifikationsnummer: 6
Beskrivelse
Beskrivelse af udbuddet:
“ATC Code: J01DC02
Generic Name: Cefuroxime
Pharmaceutical form: Injection Fluid
Strenght: 750 mg
Package: Vial
Unit: 3 g
Volume in units: Norway 7.480
ATC...”
Beskrivelse af udbuddet
ATC Code: J01DC02
Generic Name: Cefuroxime
Pharmaceutical form: Injection Fluid
Strenght: 750 mg
Package: Vial
Unit: 3 g
Volume in units: Norway 7.480
ATC Code: J01DC02
Generic Name: Cefuroxime
Pharmaceutical form: Injection Fluid
Strenght: 1500 mg
Package: Vial
Unit: 3 g
Volume in units: Norway 10
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. However, the aim is to conclude framework agreements with different suppliers for the procurement numbers 1 and 2, which are linked procurement numbers.
If there is only one compliant tender for either procurement numbers 1 or 2, the framework agreement for the procurement number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two procurement numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ra-tio”.
If there are several compliant tenders for both procurement numbers 1 and 2, the award under pro-curement number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both procurement numbers 1 and 2, and there are several com-pliant tenders for both procurement numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for procurement number 1, since the framework agreement for procurement number 2 is awarded to the supplier with the “second best price-quality ratio” under the procurement number concerned.
If there is only one compliant tender for both procurement numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both procurement numbers 1 and 2.
For every single pharmaceutical, a maximum price has been determined (price per unit ex. VAT) stated in Appendix A. Tenders with prices that exceed the set maximum price will be considered non-compliant and will not be able to form a basis for conclusion of framework agreement, see the tender specifications section 10.3
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”), the Norwegian "Farmalogg" and the Icelandic “Lyfjaverðskrá” not later than 21 February 2022 in order to ensure supply from the beginning of the Purchase Period.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 143 400 💰
7️⃣ Omfanget af udbuddet
Titel: 7
Titel
Partiets identifikationsnummer: 7
Beskrivelse
Beskrivelse af udbuddet:
“ATC Code: N02BE01
Generic Name: Paracetamole
Pharmaceutical form: Infusion Fluid
Strenght: 10 mg/ml
Package: 10-50 ml
Unit: 3 g
Volume in units: Norway...”
Beskrivelse af udbuddet
ATC Code: N02BE01
Generic Name: Paracetamole
Pharmaceutical form: Infusion Fluid
Strenght: 10 mg/ml
Package: 10-50 ml
Unit: 3 g
Volume in units: Norway 2.667
ATC Code: N02BE01
Generic Name: Paracetamole
Pharmaceutical form: Infusion Fluid
Strenght: 10 mg/ml
Package: 100 ml
Unit: 3 g
Volume in units: Norway 583.333
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. However, the aim is to conclude framework agreements with different suppliers for the procurement numbers 1 and 2, which are linked procurement numbers.
If there is only one compliant tender for either procurement numbers 1 or 2, the framework agreement for the procurement number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two procurement numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ra-tio”.
If there are several compliant tenders for both procurement numbers 1 and 2, the award under pro-curement number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both procurement numbers 1 and 2, and there are several com-pliant tenders for both procurement numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for procurement number 1, since the framework agreement for procurement number 2 is awarded to the supplier with the “second best price-quality ratio” under the procurement number concerned.
If there is only one compliant tender for both procurement numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both procurement numbers 1 and 2.
For every single pharmaceutical, a maximum price has been determined (price per unit ex. VAT) stated in Appendix A. Tenders with prices that exceed the set maximum price will be considered non-compliant and will not be able to form a basis for conclusion of framework agreement, see the tender specifications section 10.3
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”), the Norwegian "Farmalogg" and the Icelandic “Lyfjaverðskrá” not later than 21 February 2022 in order to ensure supply from the beginning of the Purchase Period.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 130 300 💰
8️⃣ Omfanget af udbuddet
Titel: 8
Titel
Partiets identifikationsnummer: 8
Beskrivelse
Beskrivelse af udbuddet:
“ATC Code: N02BE01
Generic Name: Paracetamole
Pharmaceutical form: Infusion Fluid
Strenght: 10 mg/ml
Package: 10-50 ml
Unit: 3 g
Volume in units: (Denmark...”
Beskrivelse af udbuddet
ATC Code: N02BE01
Generic Name: Paracetamole
Pharmaceutical form: Infusion Fluid
Strenght: 10 mg/ml
Package: 10-50 ml
Unit: 3 g
Volume in units: (Denmark 2.611) (Iceland 10)
ATC Code: N02BE01
Generic Name: Paracetamole
Pharmaceutical form: Infusion Fluid
Strenght: 10 mg/ml
Package: 100 ml
Unit: 3 g
Volume in units: (Denmark 230.190) (Iceland 166.666)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. However, the aim is to conclude framework agreements with different suppliers for the procurement numbers 1 and 2, which are linked procurement numbers.
If there is only one compliant tender for either procurement numbers 1 or 2, the framework agreement for the procurement number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two procurement numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ra-tio”.
If there are several compliant tenders for both procurement numbers 1 and 2, the award under pro-curement number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both procurement numbers 1 and 2, and there are several com-pliant tenders for both procurement numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for procurement number 1, since the framework agreement for procurement number 2 is awarded to the supplier with the “second best price-quality ratio” under the procurement number concerned.
If there is only one compliant tender for both procurement numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both procurement numbers 1 and 2.
For every single pharmaceutical, a maximum price has been determined (price per unit ex. VAT) stated in Appendix A. Tenders with prices that exceed the set maximum price will be considered non-compliant and will not be able to form a basis for conclusion of framework agreement, see the tender specifications section 10.3
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”), the Norwegian "Farmalogg" and the Icelandic “Lyfjaverðskrá” not later than 21 February 2022 in order to ensure supply from the beginning of the Purchase Period.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 53 300 💰
9️⃣ Omfanget af udbuddet
Titel: 9
Titel
Partiets identifikationsnummer: 9
Beskrivelse
Beskrivelse af udbuddet:
“ATC Code: L01BA01
Generic Name: Methotrexate
Pharmaceutical form: Conc. Infusion Fluid
Strenght: 100 mg/ml
Package: 10 ml
Unit: 11,42 mg
Volume in units:...”
Beskrivelse af udbuddet
ATC Code: L01BA01
Generic Name: Methotrexate
Pharmaceutical form: Conc. Infusion Fluid
Strenght: 100 mg/ml
Package: 10 ml
Unit: 11,42 mg
Volume in units: Norway 245.184
ATC Code: L01BA01
Generic Name: Methotrexate
Pharmaceutical form: Conc. Infusion Fluid
Strenght: 100 mg/ml
Package: 50 ml
Unit: 11,42 mg
Volume in units: Norway 1.444.834
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. However, the aim is to conclude framework agreements with different suppliers for the procurement numbers 1 and 2, which are linked procurement numbers.
If there is only one compliant tender for either procurement numbers 1 or 2, the framework agreement for the procurement number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two procurement numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ra-tio”.
If there are several compliant tenders for both procurement numbers 1 and 2, the award under pro-curement number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both procurement numbers 1 and 2, and there are several com-pliant tenders for both procurement numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for procurement number 1, since the framework agreement for procurement number 2 is awarded to the supplier with the “second best price-quality ratio” under the procurement number concerned.
If there is only one compliant tender for both procurement numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both procurement numbers 1 and 2.
For every single pharmaceutical, a maximum price has been determined (price per unit ex. VAT) stated in Appendix A. Tenders with prices that exceed the set maximum price will be considered non-compliant and will not be able to form a basis for conclusion of framework agreement, see the tender specifications section 10.3
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”), the Norwegian "Farmalogg" and the Icelandic “Lyfjaverðskrá” not later than 21 February 2022 in order to ensure supply from the beginning of the Purchase Period.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 644 100 💰
1️⃣0️⃣ Omfanget af udbuddet
Titel: 10
Titel
Partiets identifikationsnummer: 10
Beskrivelse
Beskrivelse af udbuddet:
“ATC Code: L01BA01
Generic Name: Methotrexate
Pharmaceutical form: Conc. Infusion Fluid
Strenght: 100 mg/ml
Package: 10 ml
Unit: 11,42 mg
Volume in units:...”
Beskrivelse af udbuddet
ATC Code: L01BA01
Generic Name: Methotrexate
Pharmaceutical form: Conc. Infusion Fluid
Strenght: 100 mg/ml
Package: 10 ml
Unit: 11,42 mg
Volume in units: (Denmark 144.370) (Iceland 875)
ATC Code: L01BA01
Generic Name: Methotrexate
Pharmaceutical form: Conc. Infusion Fluid
Strenght: 100 mg/ml
Package: 50 ml
Unit: 11,42 mg
Volume in units: (Denmark 775.222) (Iceland 43.782)
Each procurement number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other procurement numbers. This means that a tenderer may submit a tender for one, several or all procurement numbers (lots), and that framework agreements will be awarded separately for each procurement number. However, the aim is to conclude framework agreements with different suppliers for the procurement numbers 1 and 2, which are linked procurement numbers.
If there is only one compliant tender for either procurement numbers 1 or 2, the framework agreement for the procurement number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two procurement numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ra-tio”.
If there are several compliant tenders for both procurement numbers 1 and 2, the award under pro-curement number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both procurement numbers 1 and 2, and there are several com-pliant tenders for both procurement numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for procurement number 1, since the framework agreement for procurement number 2 is awarded to the supplier with the “second best price-quality ratio” under the procurement number concerned.
If there is only one compliant tender for both procurement numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both procurement numbers 1 and 2.
For every single pharmaceutical, a maximum price has been determined (price per unit ex. VAT) stated in Appendix A. Tenders with prices that exceed the set maximum price will be considered non-compliant and will not be able to form a basis for conclusion of framework agreement, see the tender specifications section 10.3
Under the title "quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.
The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (“medicinpriser.dk”), the Norwegian "Farmalogg" and the Icelandic “Lyfjaverðskrá” not later than 21 February 2022 in order to ensure supply from the beginning of the Purchase Period.
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 240 900 💰
Juridiske, økonomiske, finansielle og tekniske oplysninger Betingelser for deltagelse
Liste og kortfattet beskrivelse af betingelserne:
“When submitting a tender, suppliers must use the European Single Procurement Document (ESPD) in the tendering system for the declaration regarding the...”
Liste og kortfattet beskrivelse af betingelserne
When submitting a tender, suppliers must use the European Single Procurement Document (ESPD) in the tendering system for the declaration regarding the compulsory grounds for exclusion set out in sections 135-136 of the Danish Public Procurement Act (udbudsloven) (the Act can be found at www.retsinformation.dk). Further information on the completion and application of the ESPD in the tender process is available in the guide drawn up by Amgros in this respect and in the ‘Instructions for the European Single Procurement Document’ drawn up by the Danish Competition and Consumer Authority (Konkurrence- og Forbrugerstyrelsen). The successful tenderer(s) to whom the contracting authorities intend to award the framework agreement must also, before the award, provide documentation to the contracting authorities regarding the absence of compulsory grounds for exclusion as set out in sections 152-153 of the Public Procurement Act. The contracting authorities are not entitled to exclude a supplier who is subject to one or more of the mandatory exclusion grounds set out in sections 135-136 of the Public Procurement Act if the supplier has provided sufficient documentation that the supplier is reliable, even if the supplier is subject to one or more of the grounds for exclusion set out in section 138 of the Public Procurement Act. The contracting authorities reserve the right to carry out a so-called ‘self-cleaning’ process if relevant.
Vis mere Betingelser i forbindelse med kontrakten
Betingelser for opfyldelse af kontrakten:
“Reference is made to the provisions of the draft framework agreement and section II.2.4).
No specific legal form is required. If the contract is awarded to...”
Betingelser for opfyldelse af kontrakten
Reference is made to the provisions of the draft framework agreement and section II.2.4).
No specific legal form is required. If the contract is awarded to a group of suppliers, each participant must undertake joint and several liability and appoint a joint representative.
Procedure Type af procedure
Åben procedure
Administrative oplysninger
Frist for modtagelse af bud eller ansøgninger om deltagelse: 2021-08-31
12:00 📅
Sprog, på hvilke bud eller ansøgninger om deltagelse kan indgives: dansk 🗣️
Sprog, på hvilke bud eller ansøgninger om deltagelse kan indgives: engelsk 🗣️
Sprog, på hvilke bud eller ansøgninger om deltagelse kan indgives: norsk 🗣️
Sprog, på hvilke bud eller ansøgninger om deltagelse kan indgives: svensk 🗣️
Betingelser for åbning af buddene: 2021-08-31
12:00 📅
Betingelser for åbning af buddene (sted): Amgros I/S, Dampfærgevej 27-29, DK-2100 Copenhagen Ø.
Betingelser for åbning af tilbud (Oplysninger om bemyndigede personer og åbningsprocedure):
“The tenderers are not permitted to attend the opening of the tenders. Tenders will be registered upon receipt, and tenders received on time will be opened...”
Betingelser for åbning af tilbud (Oplysninger om bemyndigede personer og åbningsprocedure)
The tenderers are not permitted to attend the opening of the tenders. Tenders will be registered upon receipt, and tenders received on time will be opened collectively after expiry of the deadline for submission of tenders. With the notice regarding the tender evaluation, the tenderers will receive a comprehensive overview of the operators that have submitted compliant tenders.
Supplerende oplysninger Oplysninger om elektroniske arbejdsgange
Der vil blive anvendt elektronisk bestilling
Elektronisk fakturering vil blive accepteret
Der vil blive anvendt elektronisk betaling
Yderligere oplysninger
“This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to...”
This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to Danish law and any complaints of the procurement procedure shall be lodged with the Danish Complaints Board for Public Procurement (Klagenævnet for udbud),see section VI.4.3.
In relation to section II.2.4, it should be noted, that the Contracting Authorities have considered whether the procurement group could be further subdivided. The contracting authorities have deemed that this is not the case based on the considerations of economies of scale, which will not be realizable with a further subdivision as well as costs and patient safety considerations related to the subsequent management of contract- and pharmaceuticals.
In relation to sections II.1.5) and II.2.6) it should be noted that the estimated value indicated in section II.1.5) is the total estimated value of all procurement numbers (lots) for the duration of the framework agreement, including the option of renewal, see section II.2.7). Section II.2.6) sets out the estimated value for each procurement number, including the option of renewal, see section II.2.7. The value is based on the AIP (‘Apotekernes Indkøbspris’ published by the Danish Medicines Agency) of the pharmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under a framework agreement may deviate significantly from the estimate, see section II.2.4), paragraph 5.6 of the tender specifications and clause 4.2 of the framework agreement.
Questions concerning the tender documents must be submitted through the tendering system, see the provisions of the tender specifications in this regard.
The access to submit tender requires that the operator is registered as a user of Amgros' tendering system. The registration as a user may take a few days, and the tenderer must therefore make sure to register in good time. Reference is made to the information provided in the tendering system, including the user guide.
In relation to section VI.2 it should be noted that electronic invoicing is required.
Vis mere Gennemgå organ
Navn: Klagenævnet for Udbud
Postadresse: Nævnenes Hus, Toldboden 2
Postby: Viborg
Postnummer: 8800
Land: Danmark 🇩🇰
Telefon: +45 72405600📞
E-mail: klfu@naevneneshus.dk📧
URL: https://klfu.naevneneshus.dk🌏 Gennemgangsprocedure
Præcise oplysninger om fristerne for gennemgangsprocedurer:
“Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no. 593 of 2 June 2016 as amended) the following deadlines apply to the...”
Præcise oplysninger om fristerne for gennemgangsprocedurer
Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no. 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:
Complaints of the tendering procedure must be lodged with the Complaints Board for Public Procurement within 6 months after the contracting entity has entered into a framework agreement calculated from the day after the day when the contracting entity has notified the affected applicants and tenderers, see section 7(2), para.(3) of the Act. Not later than at the time of lodging a complaint with the Danish Complaints Board for Public Procurement, the complainant must notify the contracting authorities in writing that a complaint has been lodged with the Danish Complaints Board for Public Procurement and whether the complaint was lodged during the standstill period, see section 6(4) of the Act. In cases where the complaint was not lodged within the standstill period, the complainant must furthermore indicate whether a suspensory effect of the complaint has been requested, see clause 6(4) of the Act.
Vis mere Tjeneste, hvorfra der kan indhentes oplysninger om klageproceduren
Navn: Konkurrence- og Forbrugerstyrelsen
Postadresse: Carl Jacobsens vej 35
Postby: Valby
Postnummer: 2500
Land: Danmark 🇩🇰
Telefon: +45 41715000📞
URL: http://www.kfst.dk🌏
Kilde: OJS 2021/S 113-296265 (2021-06-09)
Bekendtgørelse om indgåede kontrakter (2021-12-20) Objekt Omfanget af udbuddet
Titel: Joint Nordic Procurement of Pharmaceuticals - 2022 - NF2.603.a
Samlet værdi af indkøbsaftalen (ekskl. moms): EUR 6 500 000 💰
Oplysninger om partier
Denne kontrakt er opdelt i partier ✅ Kriterier for tildeling
Kvalitetskriterium (navn): Security of Supply
Kvalitetskriterium (vægtning): 20
Kvalitetskriterium (navn): Environment
Kvalitetskriterium (vægtning): 30
Pris (justeringskoefficient): 50
Kvalitetskriterium (navn): Security of supply
Kvalitetskriterium (navn): Securiyt of Supply
Kvalitetskriterium (navn): Enviromnent
Kvalitetskriterium (navn): security of supply
Kvalitetskriterium (navn): Evironment
Kvalitetskriterium (navn): environment
Procedure Administrative oplysninger
Tidligere offentliggørelse vedrørende denne procedure: 2021/S 113-296265
Tildeling af kontrakt
1️⃣
Kontraktnummer: 1
Partiets identifikationsnummer: 1
Titel: 1
Dato for indgåelse af kontrakten: 2021-12-14 📅
Oplysninger om udbud
Antal modtagne bud: 2
Navn og adresse på kontrahenten
Navn: Fresenius Kabi
Nationalt registreringsnummer: 21347809
Postby: Copenhagen S
Postnummer: 2300
Land: Danmark 🇩🇰
Region: Danmark🏙️
Entreprenøren er en SMV
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 790 400 💰
Kontraktens/parcellens samlede værdi: EUR 330 000 💰
2️⃣
Kontraktnummer: 2
Partiets identifikationsnummer: 2
Titel: 2
Navn og adresse på kontrahenten
Navn: Life Medical ApS
Nationalt registreringsnummer: 32560946
Postby: Måløv
Postnummer: 2670
Entreprenøren er en SMV ✅ Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 949 000 💰
Kontraktens/parcellens samlede værdi: EUR 985 000 💰
3️⃣
Kontraktnummer: 3
Partiets identifikationsnummer: 3
Titel: 3
Navn og adresse på kontrahenten
Navn: Navamedic AB
Postby: Göteborg
Postnummer: 433 63
Land: Sverige 🇸🇪
Region: Sverige 🏙️ Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 900 💰
Kontraktens/parcellens samlede værdi: EUR 113 000 💰
4️⃣
Kontraktnummer: 4
Partiets identifikationsnummer: 4
Titel: 4
Navn og adresse på kontrahenten
Navn: Navamedic
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 8 000 000 💰
Kontraktens/parcellens samlede værdi: EUR 95 000 💰
6️⃣
Kontraktnummer: 6
Partiets identifikationsnummer: 6
Titel: 6
Oplysninger om udbud
Antal modtagne bud: 1
Navn og adresse på kontrahenten
Navn: Navemedic
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 143 400 💰
Kontraktens/parcellens samlede værdi: EUR 90 025 💰
7️⃣
Kontraktnummer: 7
Partiets identifikationsnummer: 7
Titel: 7
Oplysninger om udbud
Antal modtagne bud: 3
Navn og adresse på kontrahenten
Navn: B Braun Medical A/S
Nationalt registreringsnummer: 20343249
Postby: Frederiksberg
Postnummer: 2000
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 130 300 💰
Kontraktens/parcellens samlede værdi: EUR 1 370 000 💰
8️⃣
Kontraktnummer: 8
Partiets identifikationsnummer: 8
Titel: 8
Navn og adresse på kontrahenten
Navn: Baxter A/S
Nationalt registreringsnummer: 72246012
Postby: Søborg
Postnummer: 2860
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 53 300 💰
Kontraktens/parcellens samlede værdi: EUR 1 300 000 💰
9️⃣
Kontraktnummer: 9
Partiets identifikationsnummer: 9
Titel: 9
Navn og adresse på kontrahenten
Navn: Sandoz A/S
Nationalt registreringsnummer: 27744532
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 644 100 💰
Kontraktens/parcellens samlede værdi: EUR 334 000 💰
1️⃣0️⃣
Kontraktnummer: 10
Partiets identifikationsnummer: 10
Titel: 10
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 240 900 💰
Kontraktens/parcellens samlede værdi: EUR 425 000 💰
Supplerende oplysninger Yderligere oplysninger
“This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to...”
This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to Danish law and any complaints of the procurement procedure shall be lodged with the Danish Complaints Board for Public Procurement (Klagenævnet for udbud),see section VI.4.3.
In relation to section II.2.4, it should be noted, that the Contracting Authorities have considered wheth-er the procurement group could be further subdivided. The Contracting Authorities have deemed that this is not the case based on the considerations of economies of scale, which will not be realizable with a further subdivision as well as costs and patient safety considerations related to the subsequent man-agement of contract- and pharmaceuticals.
In relation to sections II.1.5 and II.2.6 it should be noted that the estimated value indicated in section II.1.5 is the total estimated value of all procurement numbers (lots) for the duration of the framework agreement, including the option of renewal, see section II.2.7. Section II.2.6 sets out the estimated value for each procurement number, including the option of renewal, see section II.2.7. The value is based on the AIP ("Apotekernes Indkøbspris" published by the Danish Medicines Agency) of the pharmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under a framework agreement may deviate significantly from the estimate, see section II.2.4, paragraph 5.6 of the tender specifications and clause 4.2 of the framework agreement.
Questions concerning the tender documents must be submitted through the tendering system, see the provisions of the tender specifications in this regard.
The access to submit tender requires that the operator is registered as a user of Amgros' tendering system. The registration as a user may take a few days, and the tenderer must therefore make sure to register in good time. Reference is made to the information provided in the tendering system, including the user guide.
In relation to section VI.2 it should be noted that electronic invoicing is required.
Vis mere
Kilde: OJS 2021/S 250-660819 (2021-12-20)